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Thyroid disorders are commonly associated with coagulopathy. Patients with hyperthyroidism have increased risk for developing
thromboembolicaccidents,whicharefavouredbyasimultaneouspresenceofantiphospholipidantibodiessyndrome.inthispaper,
we describe the case of a patient with Graves’ disease, who developed strokes with antiphospholipid antibodies syndrome.
1.Introduction
Hyperthyroidism is associated with an increased risk of
thromboembolic complications. The association between
Graves’ disease and ischemic stroke is very rare. It might
be due to diﬀerent aetiologies. The authors wish that the
discussion here in may have inﬂuence on treatment choice.
2. Observation
We report a case of 39-year-old man without familial history
of thyroid dysfunction, autoimmune disease, or thrombosis.
He presented with an acute right hemiplegia for which
he was hospitalized in neurology department. Computed
tomography (CT) scan had conﬁrmed the presence of
lacunar infarction in the internal capsule of the left cerebral
hemisphere.
He was referred to our endocrinology unit because of
signs of thyrotoxicosis including palpitation, polydipsia, and
signiﬁcant weight loss (6 kilograms).
Physical examination revealed a body mass index of
25kg/m2, a blood pressure within normal range of 130/
80mm Hg, heart rate of 96beats/min, bilateral exophthal-
mos, homogeneous goitre, and right hemiparesis.
The electrocardiogram showed regular sinus rhythm
without atrial ﬁbrillation.
Thyroid function studies revealed undetectable serum
thyroid-stimulating hormone (TSH) (below 0.05mUI/L)
and positive antithyroid-stimulating hormone receptor anti-
bodies conﬁrming the diagnosis of Graves’ disease (Table 1).
Thyroid scan with technetium 99m (Tc-99m) showed
an enlarged thyroid gland with diﬀuse increased uptake.
Fasting blood glucose was 14.3mmol/L and remained
high in the subsequent assessment conﬁrming the presence
of diabetes, according to World Health Organization. The
antibodies to glutamic acid d´ ecarboxylase (GAD) were ne-
gative.
For the assessment of his cerebrovascular accident, other
investigations were performed showing positive antiphos-
pholipid (APL) antibodies with IgG anti-β2-Glycoprotien-I
positive (β2GP-I) and IgM anticardiolipin antibody positive
which remains positive 3 months later (Table 1).
Thrombophilic factors including protein C activity,
antithrombin III, protein S, and prothrombin time were
within normal range. Antinuclear antibodies were negative.
The diagnosis of Graves’ disease associated with a pri-
mary antiphospholipid syndrome (APS) was conﬁrmed. The
patient was treated with Aspirin (250mg/day) and ben-
zyl thiouracil (25mg) at the dose of 12tablets/day, with2 International Journal of Endocrinology
Table 1: Biological characteristic of the patient.
Patient Normal range
FT4 32.09 9–19 ng/l
TSH <0.005 0.5–4.5 m UI/l
Anti-TSH receptor antibodies 12 <2 UI/ml
Antithyroglobulin antibodies 194 <50 UI/l
Antithyroperoxydase antibodies 1534 <50 UI/l
Anticardiolipin antibodies (IgM) 41–45
∗ <12 UI/l
β2GP-I antibodies (IgG) 42–44
∗ <10UI /l
FT4: free thyroxin; TSH: Thyroid-stimulating hormone; β2GP-I: anti-β2-
Glycoprotien-I.
∗At control, three months after.
progressive regression. Improvement was shown in clinical
symptoms and laboratory studies; Glycaemia levels and
glycated haemoglobin returned to normal without any
antidiabetic treatment.
3. Discussion
The association between cerebrovascular disease and Graves’
disease is very rare. Sometimes, the cerebral arterial throm-
bosis can be explained by rhythm disorders like atrial
ﬁbrillation that is frequent in Graves’ disease. This disorder
is present in 9% to 22% of the cases of hyperthyroidism
compared with 0.4% in the general population. It can reveal
the hyperthyroidism; and 15 percent of strokes occur in
people with atrial ﬁbrillation [1].
It is also being increased in cases of preexistent heart
disorder or in preferential hypersecretion of T3 [2]. Our
patient had normal sinus rhythm in electrocardiogram.
The cerebral symptoms could be explained by autoim-
mune encephalopathy. But the patients are usually euthyroid
or hypothyroid with high antibody titers. Patients show a
mild to moderate elevation of cerebrospinal ﬂuid protein
levels; rarely ﬁndings are suggestive of demyelination, such
as oligoclonal bands and myelin basic protein.
The clinical picture is presented with variable symptoms
from behavioral and cognitive changes, myoclonus, pyrami-
dal tract dysfunction, and cerebellar signs to psychosis and
coma, with relapsing and progressive course. The diagnosis
is often overlooked at presentation but it is crucial [3]. In
our case, we found right hemiplegia in the exam and left
lacuna infarct in computed tomography without clinical and
laboratory signs of autoimmune cerebral vasculitis.
During the hyperthyroidism, the inﬂuence of thyroid
hormone on the coagulation-ﬁbrinolytic system is mediated
by the interaction between the hormone and its receptors;
various abnormalities have been described, ranging from
subclinical abnormalities to major hemorrhages or fatal
thromboembolic events. Various changes in the coagulation-
ﬁbrinolytic system have been described in patients with an
excess of thyroid hormones. An increased risk of thrombosis
is found in hyperthyroidism [4, 5].
TheCarotidarterydissectionisacauseofischemicstroke
in young people; the possibility that a disorder of immunity
might have a role in the mechanism of inﬂammatory
alterations has been recently suggested. The hypothesis of
an association between carotid artery dissection and thyroid
disease has been suggested in few case reports [6, 7].
Our patient did not have headache or neck pain, and the
neuroimaging did not show dissection of carotid vessels.
The stroke in a young patient with Graves’ hyperthy-
roidism can be caused by MoyaMoya disease. It caused
multiple intracranial stenoses although this patient had a
focal neurologic deﬁcit and a single lacunar infarction on CT
scan [8, 9].
Thyrotoxicosis, probably through a factor VIII-mediated
hypercoagulability, may be a predisposing factor for cerebral
venous thrombosis [10].
The complex haemostatic balance can be inﬂuenced by
autoimmune mechanisms such as APS, but this rarely occur.
Graves’ disease can be associated with APS. The APS
occurs at the presence of at least one of the clinical criteria
and one of the laboratory criteria that are present in Table 2
[11].
This syndrome may arise in autoimmune disease mainly
in the systemic lupus erythematosusor may occur de novo in
which case it is known as primary APS.
Our patient had primary APS. These antibodies may lead
to a number of clinical syndromes including venous and
arterial thrombosis [12, 13].
In the literature, there are few cases published with
association between APS and Graves’ disease [4, 14–16].
The ﬁrst case is a 48-year-old woman having recur-
rent venous thrombosis due to primary APS associated
with hyperthyroidism. We noted the presence of Human
Leukocyte Antigen (HLA) DR7 and a high rate of anti-TSH
receptors. As for her hyperthyroidism, she was treated with
carbimazole and propranolol; As for the APS, she was given
heparin rather than coumadin with recanalization of her
thromboses [4].
The second is of a 33-year-old woman known as having
Graves’ disease; she subsequently developed a cerebrovascu-
lar disease which had been explained by the increase of APL
antibodies [14].
On immunogenetic analyses of families presenting with
auto-immune diseases and APS, we demonstrated that the
presence of the class HLA DR4 and DR7 predisposes the
patients having Graves’ disease to develop APS [17].
Other possibilities are advanced to demonstrate the
relation between the APS and Graves’ disease. The ﬁrst
possibility is suggesting the existence of a crossing reaction
between β2-glycoprotein-I and the epitope of TSH receptors.
The second possibility is that anti-TSH receptors antibodies
can generate antibodies to epitopes of antiphospholipids
[17, 18].
4. Conclusion
TheassociationbetweenAPSandGraves’diseaseisveryrare.
It may have a dangerous consequence like cerebrovascular
disease. We suggest that patients with Graves’ disease should
be examined for the presence of APS, especially when there
is thrombosis accident.International Journal of Endocrinology 3
Table 2: Clinical and laboratory criteria of antiphospholipid antibody syndrome [6].
Clinical
criteria
(1) Vascular thrombosis: one or more clinical episodes of arterial, venous, or small vessel thrombosis, in any
tissue or organ
(2) Pregnancy morbidity: one or more unexplained deaths of beyond the 10th week of gestation, one or more
premature births of a morphologically normal neonate before the 34th week of gestation, or three or more
unexplained consecutive spontaneous abortions before the 10th week of gestation
Laboratory
criteria
(1) Lupus anticoagulant present in plasma, on two or more occasions at least 12 weeks apart
(2) Anticardiolipin antibody of IgG and/or in high titer >40 GPL or MPL
(3) Anti-β2-glycoprotein-I antibody of IgG and/or IgM isotype present on two or more occasions
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